Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person ERBB2 TMD/JMD mutants bind TKIs

Class:IdReaction:9665702
_displayNameERBB2 TMD/JMD mutants bind TKIs
_doReleaseTRUE
_timestamp2022-11-09 16:55:19
authored[InstanceEdit:9665478] Orlic-Milacic, Marija, 2019-10-31
compartment[Compartment:70101] cytosol
[Compartment:876] plasma membrane
created[InstanceEdit:9665710] Orlic-Milacic, Marija, 2019-10-31
disease[Disease:1500689] cancer
edited[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
entityFunctionalStatus[EntityFunctionalStatus:9820554] gain_of_function of ERBB2 TMD/JMD mutants (TKI sensitive):ERBIN:HSP90:CDC37 [plasma membrane]
input[Complex:9665939] ERBB2 TMD/JMD mutants (TKI sensitive):ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens]
[DefinedSet:1237431] afatinib, neratinib, lapatinib [cytosol] [Homo sapiens]
isChimericFALSE
literatureReference[LiteratureReference:9646435] Activating HER2 mutations in HER2 gene amplification negative breast cancer
[LiteratureReference:9665999] Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib
[LiteratureReference:9666001] Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
modified[InstanceEdit:9665729] Orlic-Milacic, Marija, 2019-10-31
[InstanceEdit:9665748] Orlic-Milacic, Marija, 2019-10-31
[InstanceEdit:9665953] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666031] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666039] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666040] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666041] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666042] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666742] Orlic-Milacic, Marija, 2019-11-06
[InstanceEdit:9667512] Orlic-Milacic, Marija, 2019-11-12
[InstanceEdit:9676412] Orlic-Milacic, Marija, 2020-02-13
[InstanceEdit:9817342] Orlic-Milacic, Marija, 2022-09-16
[InstanceEdit:9820558] Orlic-Milacic, Marija, 2022-11-09
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
nameERBB2 TMD/JMD mutants bind TKIs
normalReaction
output[Complex:9665940] ERBB2 TMD/JMD mutants (TKI sensitive):TKI:ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens]
releaseDate2020-03-17
reviewed[InstanceEdit:9666036] Bose, Ron, 2019-10-25
[InstanceEdit:9666034] Krishna, Anagha, 2019-10-25
[InstanceEdit:9666741] Kancha, Rama Krishna, 2019-11-03
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9665712] R-HSA-9665702.3
summation[Summation:9665743] The following ERBB2 TMD/JMD mutants are sensitive to lapatin...
(hasEvent)[Pathway:9665686] Signaling by ERBB2 TMD/JMD mutants [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by ERBB2 TMD/JMD mutants bind TKIs (9665702)